ProCE Banner Activity

Managing Light-Chain Amyloidosis: Experts Respond to Your Questions on Optimizing Care

Clinical Thought
Read this commentary with expert insights and answers to audience questions from a live webinar on diagnosing and managing light-chain amyloidosis in the clinic today.

Released: February 09, 2022

Expiration: February 08, 2023

No longer available for credit.

Share

Faculty

Ankit Kansagra

Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Vaishali Sanchorawala

Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Janssen administered by Scientific Affairs

Faculty Disclosure

Primary Author

Ankit Kansagra, MD

Eugene P. Frenkel MD Scholar of Clinical Medicine
Assistant Professor of Medicine
Division of Hematology/Oncology
University Texas Southwestern Medical Center
Dallas, Texas

Ankit Kansagra, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, and Janssen and consulting fees from AbbVie, Alnylam, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Oncopeptides, and Takeda.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji K. Kumar, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, MedImmune, Oncopeptides, Takeda, and TeneoBio and consulting fees from AbbVie, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Oncopeptides, and Takeda.

Vaishali Sanchorawala, MD

Professor of Medicine
Director, Amyloidosis Center
Boston University School of Medicine
Director, Autologous Stem Cell Transplantation Program
Section of Hematology-Oncology
Boston Medical Center
Boston, Massachusetts

Vaishali Sanchorawala, MD, has disclosed that she has received funds for research support from Caelum, Celgene, Janssen, Karyopharm, Oncopeptides, Prothena, Sorento, and Takeda and consulting fees from Caelum, Janssen, Pfizer, and Prothena.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Elizabeth O’Connell, PhD

Elizabeth O’Connell, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.